



RayBiotech, Inc.

3607 Parkway Lane suite 200
Norcross, GA 30092
Tel: 770-729-2992, 1-888-494-8555
Fax: 770-206-2393
Website: www.raybiotech.com
Email: info@raybiotech.com

Certificate of Analysis and Data Sheet

Influenza A Virus H3N2 Brisbane 10/07

Catalog No.
228-10144

Introduction

H3N2 is a subtype of the influenza A virus. Its name derives from the forms of the two kinds of proteins on the surface of its coat, hemagglutinin(H) and neuraminidase(N). H3N2 exchanges genes for internal proteins with other influenza subtypes. H3N2 has tended to dominate in prevalence over H1N1, H1N2, and influenza B. H3N2 strain descended from H2N2 by antigenic shift, in which genes from multiple subtypes re-assorted to form a new virus. Both the H2N2 and H3N2 strains contained genes from avian influenza viruses.

Description

Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza A virus, strain A/Brisbane/10/07. The Influenza Virus was purified by Ultracentrifugation with 10-40 % sucrose gradient.

Inactivation

Thimerosal and beta propiolactone treatment

This product has been treated in a manner consistent with methods of inactivation. Generally accepted good laboratory practices appropriate to microbiological/viral safe handling practices and techniques are required at work.

Physical Appearance

Sterile Filtered colorless solution Formulation The H3N2 A/Brisbane/10/07 solution contains STE, 0.1 % sodium azide (NaN₃) and 0.005 % thimerosal.

Purity

Greater than 90.0% as determined by Analysis by SDS-PAGE.

Stability

A/Brisbane/10/07 although stable 4°C for 4 weeks, should be stored desiccated below -18°C.

Please prevent freeze-thaw cycles.

Immunological Activity

Tested with anti-influenza A monoclonal antibodies in ELISA.

Serological studies of influenza A virus, immunogen for antibody production.

**The products are furnished for LABORATORY RESEARCH USE ONLY.
Not for diagnostic or therapeutic use.**